Core Viewpoint - Yinosh's stock price has shown significant volatility, with a year-to-date increase of 39.24% and a recent decline of 2.00% on November 14, 2023, indicating potential market fluctuations and investor sentiment [1]. Group 1: Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010, with its listing date set for September 3, 2024 [1]. - The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1]. Group 2: Financial Performance - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, representing a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.79 million yuan, a decline of 111.14% compared to the previous year [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - Notable changes in institutional holdings include new entries from Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund among the top ten circulating shareholders [3].
益诺思跌2.00%，成交额578.32万元，主力资金净流入34.50万元